Updated:
Organigram Global
Organigram Holdings Inc. is an investment firm. It has made one investment, deploying $17 million in total capital. The firm focuses on the biotechnology...
Organigram Global
Organigram Holdings Inc. is an investment firm. It has made one investment, deploying $17 million in total capital. The firm focuses on the biotechnology sector.
General information
Firm type
Asset Manager
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, ON, Canada
Additional offices
Moncton, NB · Lac-Supérieur, QC · Winnipeg, MB · Aylmer, ON · London, ON
Principals
James Yamanaka
Chief Executive Officer
Beena Goldenberg
Chief Executive Officer
Greg Guyatt
Chief Financial Officer
Tim Emberg
President of Organigram Canada
Paolo de Luca
Chief Strategy Officer
Helen Martin
Chief Legal Officer
Valerie Rother
Chief People Officer
Megan McCrae
Senior VP of Corporate Strategy & International Growth
Borna Zlamalik
Senior VP of Innovation and International R&D
Bradley Gunter
Senior VP of Sales
Steven Nazarian
Senior VP of Innovation and Product Development Engineering
Geoffrey Machum
Director
Sector focus
Frequently asked questions
Who runs investment decisions at Organigram Global?
Strategic and investment decisions sit with the executive leadership team led by CEO Beena Goldenberg, with the board of directors providing governance. James Yamanaka is also listed as CEO on the firm's website, suggesting a leadership transition or dual CEO structure. The firm does not disclose an independent investment committee separate from its board.
How is Organigram structured as a corporate entity?
Organigram Global Inc. is a publicly traded company listed on the Toronto Stock Exchange, not a family office or private holding vehicle. It operates as a vertically integrated cannabis consumer packaged goods company, cultivating, extracting, manufacturing, and distributing branded products across Canada and through international supply agreements.
Which sectors does Organigram Global explicitly focus on?
The firm concentrates entirely on regulated cannabis, covering flower, pre-rolls, edibles, vapes, extracts, and lozenges. Its portfolio includes value brands like SHRED, premium lines like Edison, and wellness-oriented products like Monjour. It does not operate outside cannabis or adjacent into broader consumer goods.
Does Organigram Global participate in fund commitments or only direct operating investments?
Organigram invests directly in wholly owned operating subsidiaries and brands, not as a limited partner in external funds. Its corporate development strategy relies on acquisitions like the 2024 Motif Labs deal and structured international partnerships, rather than passive fund commitments or venture-style minority positions.
What is Organigram's known posture on co-investments alongside external companies?
Organigram enters structured strategic agreements rather than blind-pool co-investment arrangements. Its 2023 agreements with Sanity Group, 4C Labs, and Phylos Bioscience are supply, licensing, and intellectual property partnerships, not co-investment vehicles. Each deal includes defined commercial terms for product distribution in specific non-Canadian jurisdictions.
Where does Organigram's revenue come from geographically?
The firm's primary revenue engine is the Canadian adult-use market, served by its cultivation, extraction, and manufacturing facilities in New Brunswick, Quebec, Manitoba, and Ontario. International revenue channels are developing through its German and UK agreements, but the company has not disclosed the percentage of total revenue from non-Canadian sources.
Does Organigram maintain philanthropic structures or community programs?
Organigram participates in the Pledge 1% global movement, committing to donate time, product, or profit to community organizations. Its website emphasizes community investment in the locations where it operates six facilities across five provinces, though the firm does not disclose a separate philanthropic foundation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: